A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)

Registry ID

EUCTR2008-007520-26

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Klinikum der Universität München

Start date

2009-12-18

Completion date

2012-06-14

Last update

2026-08-16

Conditions

• Progressive Supranuclear Palsy

Summary

To assess the efficacy of Rasagiline using the PSP rating scale (PSPRS), aiming at a 33 % reduction of the reported deterioration (Golbe et al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7. To assess the need for additional L-DOPA therapy or the need to in-crease the dose of L-DOPA during the trial.

Locations

• , , Germany

Related clinical trials

• Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
• Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
• Neurologic Stem Cell Treatment Study
• A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
• The Swedish BioFINDER 2 Study
• Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging

View on source registry